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Abstract
Hexanucleotide repeat expansion in the C9orf72 gene is a leading cause of frontotemporal lobar degeneration
(FTLD) with amyotrophic lateral sclerosis (ALS). Reduced expression of C9orf72 has been proposed as a possible
disease mechanism. However, the cellular function of C9orf72 remains to be characterized. Here we report the
identification of two binding partners of C9orf72: SMCR8 and WDR41. We show that WDR41 interacts with the
C9orf72/SMCR8 heterodimer and WDR41 is tightly associated with the Golgi complex. We further demonstrate that
C9orf72/SMCR8/WDR41 associates with the FIP200/Ulk1 complex, which is essential for autophagy initiation. C9orf72
deficient mice, generated using the CRISPR/Cas9 system, show severe inflammation in multiple organs, including
lymph node, spleen and liver. Lymph node enlargement and severe splenomegaly are accompanied with macrophage
infiltration. Increased levels of autophagy and lysosomal proteins and autophagy defects were detected in both the
spleen and liver of C9orf72 deficient mice, supporting an in vivo role of C9orf72 in regulating the autophagy/lysosome
pathway. In summary, our study elucidates potential physiological functions of C9orf72 and disease mechanisms of
ALS/FTLD.
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Introduction
Frontotemporal lobar degeneration (FTLD) and amyo-
trophic lateral sclerosis (ALS) are two devastating neuro-
degenerative diseases, which due to overlaps in clinical
presentations, pathological features, and genetic causes,
are considered two manifestations of a continuous dis-
ease spectrum [1, 7, 15, 29, 30, 49].
Many novel genes have been recently associated with
ALS/FTLD [29, 37]. Among these, hexanucleotide repeat
expansion in the C9orf72 gene has been shown to be the
main cause of ALS/FTLD [13, 38, 51], for which three
disease mechanisms have been proposed: toxicity of
RNA foci formed by RNA repeats, toxicity induced by
dipeptide repeat aggregation as a result of repeat associ-
ated non-ATG mediated RNA translation (RAN), and
reduced expression of the C9orf72 gene [26, 39].
Recently, several animal models have been established to
investigate repeat associated gain of toxicity [10, 18, 31,
33, 35, 47] as well as the physiological functions of
C9orf72 in mammals. While neuron and glia specific
C9orf72 ablation or intracerebral mRNA knockdown
does not seem to cause motor neuron disease in mouse
models [22, 24], two recent studies on whole body
C9orf72 deficient mice demonstrate that C9orf72 defi-
ciency results in severe immune dysregulation [2, 34],
suggesting that loss of C9orf72 function could lead to
mis-regulated inflammatory responses.
Despite many attempts at characterizing the exact mo-
lecular function of C9orf72, its cellular role is still not
entirely clear. Bioinformatics studies have predicted
C9orf72 to be a member of DENN domain containing
proteins which typically function as guanine exchange
factors for Rab GTPases, key regulators of membrane
trafficking in eukaryotic cells [28, 54]. One study has
demonstrated physical interactions between C9orf72 and
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Rab7 and Rab11, GTPases involved in late endosome
maturation or endosome recycling, respectively, and a
role of C9orf72 in autophagy regulation [14]. However,
direct regulation of these Rab GTPases by C9orf72 was
not demonstrated in this study [14].
In order to gain insight into C9orf72 function, we per-
formed a proteomic screen for C9orf72 binding partners.
We showed that C9orf72 forms a tight complex with
SMCR8, another DENN domain containing protein [54],
and WDR41, a WD40 repeat protein. We further dem-
onstrated the physical interaction between C9orf72/
SMCR8/WDR41 and the FIP200/Ulk1/ATG13/ATG101
complex, which is an essential regulator of autophagy
initiation. Our results are consistent with two recent
reports on the C9orf72/SMCR8/WDR41 interaction
published while this manuscript was under preparation
[41, 53]. Furthermore, our data from C9orf72 deficient
mice support a role of C9orf72 in immune regulation
and the autophagy-lysosome pathway.
Material and methods
DNA and Plasmids
Human C9orf72 (C9-L), WDR41 and SMCR8 cDNAs
were from the human ORFome 8.1 library and cloned
into pQCXIN, pEGFP-N1 or pEGFP-N2, respectively,
with an N-terminal (C9orf72) or C-terminal (WDR41
and SMCR8) GFP tag. The short C9orf72 isoform was
cloned from C9-L into pEGFP-C1 with the following 3'
primer: tgacCTCGAGttacttgagaagaaagccttcatg. WDR41
and SMCR8 were also cloned into pcDNA3.1 myc his A
(Invitrogen) to generate C-terminal myc his tagged con-
structs. Additionally, C9orf72 and WDR41 were cloned
into p3xFLAG-CMV7.1 (Sigma) to generate N-terminal
FLAG tagged constructs. Myc-ATG13, FLAG-ATG101 and
p3xFLAG-CMV10-hFIP200 were obtained from Addgene
(plasmid #31965, 22877 and 24300, respectively).
Pharmacological Reagents and Antibodies
The following primary antibodies were used in this study:
anti-FLAG (M2) and anti-myc (9E10) from Sigma-
Aldrich, anti-GAPDH from Abcam (ab8245), anti-LC3B
(GTX127375) and anti-C9orf72 (GTX119776) from Gene-
Tex, anti-Cathepsin D (sc-6486), anti-Ulk1 (sc-33182) and
anti-C9orf72 (sc-138763) from Santa Cruz Biotechnology,
anti-C9orf72 (AP12928b) and anti-FIP200 (17250-1-AP)
from Proteintech, anti-SMCR8 from Bethyl Laboratories,
anti-WDR41 from Abgent, rat anti-CD68 from AbD
Serotec, sheep anti-progranulin from R&D systems and
anti-mouse LAMP1 (553792) from BD Biosciences. Anti-
mouse prosaposin antibody was generated by Pocono
Rabbit Farm and Laboratory and was previously charac-
terized [55]. Anti-C9orf72-long isoform [52] was a gift
from Dr. Janice Robertson (University of Toronto); anti-
GFP antibody was a gift from Dr. Anthony Bretscher
(Cornell University); and anti-GPP130 was a gift from
Dr. William Brown (Cornell University). The following
secondary antibodies were used: donkey anti-mouse 800
and donkey anti-rabbit 800 from LI-COR, AlexaFluor don-
key anti-goat 680, donkey anti-rabbit 680, donkey anti-
mouse 680, and donkey anti-rat 680 from Invitrogen, and
donkey anti-mouse 568 from Biotium. Hoechst stain was
obtained from Invitrogen. Brefeldin A (BFA) and nocoda-
zole were obtained from Sigma-Aldrich and used at a final
concentration of 300 μM and 20 mM, respectively.
Mouse strains
C9orf72 knockout mice were produced using CRISPR/
Cas9 genome editing with a guide RNA (gRNA) target-
ing exon 2 of mouse gene 3110043O21RIK. C57BL/6 J x
FvB/N mouse embryos were injected with gRNA and
Cas9 mRNA at the Cornell Transgenic Core Facility.
Editing was confirmed by sequencing PCR products
from genomic DNA and loss of protein products was
determined by Western blot of tissue lysate. Offspring
from the founder containing 1 bp deletion were used for
the study except the 10 month old founder mice. The fol-
lowing primers were used to genotype C9orf72 knockout
mice: 5′- gcggctacctttgcttac -3′ (WT forward), 5′- tggcggct
acctttgcta -3 (KO forward) and 5′- tgcccaggagacacaacata
-3′ (common reverse).
Cell culture and DNA transfection
HEK293T cells were maintained in Dulbecco’s Modified
Eagle’s Medium (Cellgro) supplemented with 10 % fetal
bovine serum (Gibco) and 1 % Penicillin–Streptomycin
(Invitrogen) in a humidified incubator at 37 °C and 5 %
CO2. Cells were transiently transfected with polyethyle-
neimine as described [48].
Immunoprecipitation and protein analysis
Cells were lysed in 50 mM Tris pH 8.0, 150 mM NaCl,
1 % Triton X-100, and 0.1 % deoxycholic acid with pro-
tease inhibitors (Roche). Lysates were incubated with
GFP-Trap beads (ChromoTek) or anti-FLAG antibody
conjugated beads (Sigma-Aldrich) for 2–3 h at 4 °C.
Beads were washed 3 times with 50 mM Tris pH 8.0,
150 mM NaCl, and 1 % Triton X-100. Samples were de-
natured in 2xSDS sample buffer (4 % SDS, 20 % glycerol,
100 mM Tris pH 6.8, 0.2 g/L bromophenol blue) by
boiling for 3 min. Samples were run on 8 % or 12 %
polyacrylamide gels and transferred to PVDF mem-
branes (Millipore). Membranes were blocked in either
Odyssey Blocking Buffer (LI-COR Biosciences) or 5 %
non-fat milk in PBS for 1 h followed by incubation with
primary antibodies overnight at 4 °C. Membranes were
washed 3 times with Tris-buffered saline with 0.1 %
Tween-20 (TBST) then incubated with secondary anti-
body for 2 h at room temperature. Membranes were
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washed 3 times with TBST and imaged using an Odyssey
Infrared Imaging System (LI-COR Biosciences).
To quantify protein levels in tissue samples, tissues
were homogenized in RIPA buffer (50 mM Tris pH 8.0,
150 mM NaCl, 1 % Triton X-100, 0.1 % SDS and 0.1 %
deoxycholic acid) with protease inhibitors on ice and
then equal volume of 2X SDS sample buffer was added
before sonication. 50 μg of each protein sample was
loaded onto a 12 % poly-acrylamide gel. Blots were ana-
lyzed by LiCor Odyssey system and normalized to
GAPDH.
SILAC and mass spectrometry analysis
N2a cells were grown a minimum of five generations in
DMEM with 10 % dialyzed FBS (Sigma) supplemented
with either light (C12, N14 arginine and lysine) or heavy
(C13, N15 arginine and lysine) amino acids. The heavy
cells were transfected in two 15 cm dishes with GFP-
C9orf72 expression constructs while the light cells were
transfected with pEGFP-C1 as a control. Two days after
transfection, cells were lysed in 50 mM Tris pH8.0,
150 mM NaCl, 1 % Triton, 0.1 % deoxycholic acid with
protease inhibitors (Roche). The lysates were subject to
anti-GFP immunoprecipitation using GFP-Trap beads
(ChromoTek). The presence of GFP and GFP-C9orf72
in immunoprecipitated samples was confirmed by SDS-
PAGE and Krypton staining (Invitrogen). Samples were
then combined and boiled 5 min with 1 % DTT followed
by alkylation by treating samples with a final concentra-
tion of 28 mM iodoacetamide. Proteins were precipi-
tated on ice for 30 min with a mixture of 50 % acetone/
49.9 % ethanol/0.1 % acetic acid. Proteins were pelleted
and washed with this buffer, re-precipitated on ice, and
dissolved in 8 M urea/50 mM Tris pH 8.0 followed by
dilution with three volumes of 50 mM Tris pH 8.0/
150 mM NaCl. Proteins were digested overnight at 37 ° C
with 1 μg mass-spec grade Trypsin (Promega). The
resulting peptide samples were cleaned up for mass
spectrometry by treatment with 10 % formic acid and
10 % trifluoroacetic acid (TFA) and washed twice with
0.1 % acetic acid on pre-equilibrated Sep-Pak C18 car-
tridges (Waters). Samples were eluted with 80 % aceto-
nitrile (ACN)/0.1 % acetic acid into silanized vials
(National Scientific) and evaporated using a SpeedVac.
Samples were re-dissolved in H2O with ~1 % formic
acid and 70 % ACN. Peptides were separated using
hydrophilic interaction liquid chromatography (HILIC)
on an Ultimate 300 LC (Dionex). Each fraction was
evaporated with a SpeedVac and resuspended in 0.1 %
TFA with 0.1 pM angiotensin internal standard. Sam-
ples were run on a Thermo LTQ Orbitrap XL mass
spectrometer and data analyzed using the SORCERER
system (Sage-N research).
Hematoxylin and eosin (H&E) staining
Mouse tissues were fixed with 4 % formaldehyde. After
dehydration with 70 % ethanol, tissues were embedded
with paraffin. The tissues were sliced to 8 μm. Followed
by deparaffiinization with xylene and ethanol (100 %,
95 %, 80 %) and rehydration with tap water, the slides
were stained in hematoxalin for 3 min, destained with
acid ethanol and rinsed with tap water, and then stained
with eosin for 30 s. The slides were then dehydrated
with ethanol and xylene and mounted.
Immunofluorescence microscopy
HeLa cells grown on glass coverslips were fixed in 3.7 %
paraformaldehyde for 15 min, washed 3 times with PBS,
and permeabilized and blocked in Odyssey Blocking
Buffer with 0.05 % saponin or 0.1 % Triton for 20 min.
Primary antibodies diluted in blocking buffer with 0.05 %
saponin were applied to the cells overnight at 4 °C. Cover-
slips were washed 3 times with PBS. Secondary antibodies
and Hoechst stain diluted in blocking buffer with 0.05 %
saponin were applied to the cells for 2 h at room
temperature. Coverslips were washed and mounted onto
slides with Fluoromount G (Southern Biotech). Images
were acquired on a CSU-X spinning disc confocal micro-
scope (Intelligent Imaging Innovations) with an HQ2 CCD
camera (Photometrics) using a 100x objective.
Mouse tissues were perfused and fixed with 4 % for-
maldehyde. After gradient dehydration with 15 % and
30 % sucrose, tissues were embedded with OCT com-
pound (Sakura Finetek USA) and sectioned with Cryo-
tome. For the immunostaining, tissue sections were
permeabilized and blocked in Odyssey blocking buffer
with 0.05 % saponin for 1 h. Primary antibodies were in-
cubated in blocking buffer overnight at 4 °C. Sections
were washed and incubated in secondary antibodies con-
jugated to Alexaflour 488, 568, or 660 (Invitrogen). Sec-
tions were washed three more times and coverslips
mounted onto slides with Fluoromount G (Southern
Biotech). Images were acquired on a CSU-X spinning
disc confocal microscope (Intelligent Imaging Innova-
tions) with an HQ2 CCD camera (Photometrics) using a
40x objective.
Statistical analysis
The data were presented as mean ± SEM. Two-group
analysis was performed using the Student’s t test. P-
values <0.05 were considered statistically significant.
Results
C9orf72 forms a complex with SMCR8 and WDR41
In humans, two C9orf72 protein isoforms are generated
from three alternatively spliced transcripts, a long form
(C9-L) and a short form (C9-S), with multiple studies
showing that the protein and mRNA level of the C9-L
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form are decreased in C9/ALS patients [5, 50, 52]. To
decipher the protein interaction network of C9orf72, a
SILAC (stable isotope labeling of amino acids in cell cul-
ture) based proteomic screen was performed in the
neuroblastoma cells line neuro-2a (N2a) using GFP-
C9orf72 (C9-L) as the bait and GFP as a control (Fig. 1a,
Additional file 1: Figure S1). Several proteins were found
to be enriched in the C9orf72 immunoprecipitations
(IPs) (Fig. 1b, Additional file 2: Table S1). The top two
hits from the screen were SMCR8 and WDR41, two pro-
teins of unknown functions (Fig. 1b). Interestingly, like
C9orf72, SMCR8 was also predicted to contain a DENN
domain [54]. The interaction between C9orf72, SMCR8,
and WDR41 was verified using co-IPs in transfected
HEK293T cells (Fig. 2a-c). SMCR8 strongly interacts
with GFP-C9orf72 but not GFP in the co-IP experiment
(Fig. 2a). Moreover, co-expression of C9orf72 consist-
ently increases the level of SMCR8, suggesting that
C9orf72 might stabilize overexpressed SMCR8. However,
the short isoform of human C9orf72 (C9-S) does not
bind SMCR8 (Fig. 2a). Thus we focus on the C9-L form
for the rest of the study (hereafter referred to as
C9orf72). While we failed to detect any interaction be-
tween WDR41 and C9orf72 or SMCR8 when WDR41 is
expressed with either C9orf72 or SMCR8 alone, WDR41
strongly co-immunoprecipitates with C9orf72 and SMCR8
when C9orf72 and SMCR8 are co-expressed, suggesting
Fig. 1 SILAC proteomic screen for C9orf72 binding partners. a
Schematic workflow of SILAC proteomic screen used to identify
C9orf72 protein interactions. b Volcano plot of SILAC hits. Hits with
more than 10 peptides are plotted. Top hits identified in the heavy
fraction are highlighted
Fig. 2 Co-immunoprecipitation between C9orf72, SMCR8 and WDR41.
a GFP-tagged human C9orf72 isoform I (GFP-C9-L) or isoform II
(GFP-C9-S) were overexpressed with SMCR8-myc in HEK293T cells and
immunoprecipitated by anti-GFP beads. b SMCR8-GFP and WDR41-myc
were coexpressed with or without FLAG-C9-L and the lysates were
immunoprecipitated using anti-GFP antibodies. c GFP-C9-L and FLAG-
WDR41 were co-expressed with or without SMCR8-myc as indicated
and the lysates were immunoprecipitated using anti-GFP antibodies
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that WDR41 interacts only with the C9orf72/SMCR8
heterodimer (Fig. 2b, 2c).
Cellular localization of C9orf72, SMCR8 and WDR41
To gain insight into the cellular function of the C9orf72/
SMCR8/WDR41 complex, we expressed these proteins
in HeLa cells and examined their distribution within the
cell. Both C9orf72 and SMCR8 show diffuse cytoplasmic
localization, when expressed alone or together (Fig. 3a
and b). Nuclear localization was observed for C9orf72,
especially the GFP-tagged C9orf72 but not SMCR8
(Fig. 3a and b). WDR41 also shows diffuse cytoplasmic
distribution (Fig. 3a and c). However, careful examin-
ation reveals enrichment of WDR41 at the cis-Golgi,
which is confirmed when labelled by the cis-Golgi pro-
tein GPP130 (Fig. 3c). This is further supported by treat-
ment of cells with BrefeldinA, which causes the Golgi to
collapse. Even after such treatment, WDR41 remains
Fig. 3 Cellular localization of C9orf72, SMCR8 and WDR41. a HeLa cells were transfected with FLAG-C9orf72 (C9-L), SMCR8-myc or WDR41-GFP.
Cells were stained with anti-FLAG or anti-myc to visualize FLAG-C9orf72 or SMCR8-myc, respectively. Maximum projection images from confocal
sections are shown. Scale bar = 10 μm. b HeLa cells were transfected with GFP-C9orf72 (C9-L) and SMCR8-myc. Cells were stained with anti-myc
antibodies to visualize SMCR8-myc. c WDR41-GFP expressing HeLa cells were treated with DMSO control, 0.3 mM BrefeldinA (BFA), or 20 mM Nocodazole
for 2 h. Cells were stained with anti-GPP130 antibodies to label cis-Golgi. Single confocal images are shown for b and c. Scale bar = 10 μm
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Fig. 4 The C9orf72/SMCR8/WDR41 complex interacts with FIP200/Ulk1. a Co-immunoprecipitation between C9orf72/SMCR8/WDR41 and FIP200
and Ulk1. HEK293T cells were transfected with FLAG-FIP200 and C9orf72, SMCR8 and/or WDR41 as indicated. Cells were lysed 40 h after transfection
and lysates were immunoprecipated with anti-GFP antibodies. Lysates and immunoprecipitates were analyzed by Western blots as indicated.
* indicated non-specific bands recognized by anti SMCR8 antibodies in the IP products. Representative images from 3 independent experiments
are shown. b Co-immunoprecipitation between C9orf72/SMCR8/WDR41 and FIP200. HEK293T cells were transfected as indicated and lysed and
immunoprecipitated using anti-FLAG antibodies. Lysates and immunoprecipitates were analyzed by Western blots. c, d Co-immunoprecipitation
between C9orf72/SMCR8/WDR41 and ATG101 (c) or ATG13 (d). HEK293T cells were transfected as indicated and lysed and immunoprecipitated using
anti-GFP antibodies. Lysates and immunoprecipitates were analyzed by Western blots. e Schematic drawing of the interaction between C9orf72/
SMCR8/WDR41 and the FIP200/Ulk1 complex. WDR41 interacts with the C9orf72/SMCR8 dimer to form ternary complex, which then interacts with the
FIP200/Ulk1/ATG13/ATG101 complex
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colocalized with GPP130, indicating that WDR41 is
tightly associated with the Golgi membrane. Similar re-
sults were obtained after treatment with nocodazole, a
microtubule destabilizing drug that causes the Golgi to
disperse (Fig. 3c).
Interaction of C9orf72/SMCR8/WDR41 with the FIP200
autophagy initiation complex
A previously reported proteomics screen identified
SMCR8 as a binding partner for FIP200 (also called
RB1CC1) [4], a protein involved in autophagy initiation
[44]. However, the interaction between SMCR8 and
FIP200 is barely detectable by co-IP when only these two
proteins are overexpressed (Fig. 4a). Interestingly, we
found that co-transfection of C9orf72 and SMCR8 allows
much stronger binding of SMCR8 to FIP200, which is fur-
ther enhanced by WDR41 overexpression, suggesting that
C9orf72/SMCR8/WDR41 forms a ternary complex to
interact with FIP200 (Fig. 4a). The weaker binding be-
tween SMCR8 and FIP200 when SMCR8 is expressed
alone in HEK293T cells is most likely explained by very
low endogenous levels of C9orf72 and WDR41 (Fig. 4a
and Additional file 1: Figure S1). Ulk1, a kinase that inter-
acts with FIP200 in the autophagy initiation complex [44],
binds the C9orf72/SMCR8/WDR41 in a similar manner
as FIP200 (Fig. 4a). Furthermore, C9orf72, SMCR8 and
WDR41 are all detected in the FIP200 immunoprecipi-
tates (Fig. 4b). ATG13 and ATG101, two other proteins
associated with FIP200/Ulk1 also interact with C9orf72/
SMCR8/WDR41 (Fig. 4c and d). These data support that
the formation of the C9orf72/SMCR8/WDR41 complex
allows their interaction with the FIP200/Ulk1/ATG13/
ATG101 complex (Fig. 4e).
Generation and characterization of C9orf72 deficient mice
Three protein isoforms of mouse C9orf72 homolog
(I, 55 kDa; II, 35 kDa and III; 50 kDa) have been
identified with isoform I (55 kDa), the functional homolog
of C9-L in humans, being the dominant form in most
tissues [3, 45]. In order to investigate the function of
C9orf72 in vivo, we generated C9orf72 deficient mice using
the CRISPR/Cas9 system [12, 32]. Guide RNA targeted
close to the start codon of the mouse C9orf72 isoform I
and III was co-injected with the Cas9 mRNA into the pro-
nuclei of fertilized eggs (Fig. 5a). All the offspring displayed
Cas9 mediated cleavage and editing from non-homologous
end joining mediated repair. We chose one founder con-
taining a one-nucleotide deletion at the beginning of the
C9orf72 open reading frame, resulting in a frame shift at
residue 33 that produces a stop codon at amino acid 40
(Fig. 5b). Based on the splicing patterns, the one nucleotide
deletion should cause the loss of protein products for
C9orf72 isoforms I (55 kDa) and III (50 kDa), but should
not affect isoform II (35 kDa). Indeed, Western blot using
several antibodies shows loss of C9orf72 isoform I protein
in homozygous offspring from the above-mentioned
founder (Fig. 5c, and Additional file 3: Figure S2). We
failed to detect isoform II and III in our Western blots
with all the C9orf72 antibodies tested and thus we can-
not determine whether these isoforms are affected by
the CRISPR/Cas9 editing. While C9orf72 isoform I is
detectable in all tissues examined, its level is highest in
spleen, followed by kidney, brain, and heart, and much
lower in the liver and muscle (Fig. 5c). This expression
pattern is consistent with a recent publication demon-
strating the highest levels of C9orf72 in CD11b+ mye-
loid cells [34].
Our C9orf72 deficient mice do not have any apparent
growth defects (data not shown) but display an obvious
lymph node and spleen enlargement phenotype (Fig. 5d),
consistent with recent reports on another two independ-
ent lines of C9orf72 knockout mice [2, 34]. While occa-
sional mild splenomegaly was observed in the 2 month
old C9orf72 deficient mice, this phenotype becomes
more severe with age, with the 4-5 month old C9orf72
deficient mouse having a spleen 2-3 times the size of its
Fig. 5 Generation of C9orf72 deficient mice. a Schematic drawing of
the mouse homologue of C9orf72, 3110043O21RIK, and the site
targeted for editing by CRISPR/Cas9. b Sequencing traces of
wildtype (top) and edited (bottom) C9orf72 from genomic PCR
show a one nucleotide deletion (highlighted with yellow) near the
Cas9 cleavage site. c Western blot analysis of C9orf72 protein levels
in wild type (WT) and C9orf72-/- (KO) mouse tissues with anti-C9-L
antibodies. d Representative images of cervical lymph nodes and
spleen from 4-5 months old WT and C9orf72-/- mice. Scale bar =
2 mm (lymph node); 1 cm (spleen)
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littermate control (Fig. 5d and Additional file 4: Figure S3).
This is also seen in two of the 10 month old founder mice
from the CRISPR mediated editing (Additional file 4:
Figure S3). The liver also shows slight enlargement but
there are no obvious gross anatomical defects in the
brain of C9orf72 deficient mice (data not shown).
Hematoxylin and eosin (H&E) staining of the C9orf72
deficient spleen reveals enlarged germinal centers (GCs)
and abundant extramedullary hematopoietic cells (Fig. 6a).
High magnification shows the enlarged GCs are packed
with immature immune cells, among which plasma cells
are often observed (Fig. 6a). Several types of hematopoietic
Fig. 6 C9 deficiency in mice results in an enlarged spleen phenotype and macrophage infiltration into the spleen. a H&E staining of spleen tissues from
5 month old of WT or C9orf72 -/- mouse with zoomed images of germinal center (GC) and red pulp (RP). (GC): Arrows indicate plasma cells and the
arrowheads indicate immature immune cells). (RP): arrowheads indicate myeloid precursors; arrows indicate erythroid precursors. Scale bar = 500 μm
(100 μm in the zoomed in images for GC and RP). b Immunostaining of 4 month old spleen sections (red pulp region) of WT and C9orf72-/- mice with
anti-mouse CD68, prosaposin (PSAP), and progranulin (PGRN) antibodies. Nuclei are labelled with DAPI. Insert shows representative CD68+ macrophage
cells. Representative pictures from three pairs of mice are shown. Scale bar = 40 μm. c Immunostaining of 4 month old spleen sections (red pulp region)
of WT and C9orf72-/- mice with anti-mouse Lamp1, and cathepsin D (CathD) antibodies. Nuclei are labelled with DAPI. Insert shows representative cells.
Representative pictures from three pairs of mice are shown. Scale bar = 40 μm
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cells are enriched in the red pulp (Fig. 6a). Immunostaining
with anti-CD68 antibodies shows macrophage accumula-
tion or infiltration in the red pulp of the spleen (Fig. 6b),
which is also seen in the peripheral regions of cervical
lymph nodes (Fig. 7a) and to a lesser extent, liver of
C9orf72 deficient mice at 4 months of age (Fig. 8b). In
C9orf72-/- liver tissues, infiltrated immune cells were ob-
served in both hepatic portal area and hepatic parenchyma
(Fig. 8a). Surrounding by the infiltrated immune cells, nec-
rotic hepatocytes are occasionally seen in C9orf72-/- liver
tissues (Fig. 8a). Despite macrophage infiltration in mul-
tiple peripheral organs, microglia, the counterpart of mac-
rophages in the central nervous system, do not show any
obvious changes in number and morphology in the
C9orf72 deficient mice (Fig. 9).
Autophagy and lysosome defects in the C9orf72 deficient
mice
Because C9orf72/SMCR8/WDR41 co-immunoprecipitates
with the FIP200/Ulk1/ATG13/ATG101 complex, we in-
vestigated possible autophagy/lysosome defects in the
C9orf72 deficient mice. Interestingly, Ulk1 deficiency has
also been reported to result in splenomegaly [23]. Western
blot analysis showed significantly increased levels of
several proteins involved in the autophagy/lysosomal
pathway in spleen and liver lysates of the 2 month old
C9orf72 deficient mice compared to littermate controls,
including LC3-I, LAMP1, and prosaposin (PSAP), even
before the appearance of an obvious splenomegaly pheno-
type, suggesting that autophagy/lysosome defects might
precede anatomical spleen abnormalities (Fig. 10a, b). Al-
though no obvious changes in lysosomal morphology were
seen in the C9orf72-/- macrophages, increased levels of
the lysosomal proteins progranulin (PGRN), PSAP,
LAMP1 and cathepsin D (CathD) are seen in CD68 posi-
tive macrophages in the lymph nodes, spleen and liver of
C9orf72 deficient mice (Fig. 6, 7 and 8). This might sug-
gest that loss of C9orf72 causes a defect in the lysosome
that requires upregulation of lysosomal proteins to com-
pensate. Conversion of LC3-I to LC3-II is an indicator of
autophagy initiation [21]. Although LC3-I levels are dra-
matically increased in C9orf72 deficient spleen lysates,
LC3-II levels are significantly reduced (Fig. 10a, b), sug-
gesting that loss of C9orf72 causes a defect in autophagy
initiation. Despite these changes in multiple peripheral tis-
sues, brain lysates do not show any apparent increases in
autophagy or lysosomal proteins in the 2 month old
C9orf72 deficient mice compared to controls (Fig. 10a, b).
Fig. 7 Increased macrophage infiltration and lysosomal proteins in the cervical lymph node of C9 deficient mice. a Immunostaining of 4 month
old cervical lymph nodes sections (peripheral region) of WT and C9orf72-/- mice with anti-mouse CD68, prosaposin (PSAP), and progranulin
(PGRN) antibodies. Nuclei is labelled with DAPI. Insert shows representative CD68+ macrophage cells. Representative pictures from three pairs of
mice are shown. Scale bar = 40 μm. b Immunostaining of 4 month old cervical lymph nodes sections (peripheral region) of WT and C9orf72-/-
mice with anti-mouse Lamp1, and cathepsin D (CathD) antibodies. Nuclei are labelled with DAPI. Insert shows representative cells. Representative
pictures from three pairs of mice are shown. Scale bar = 40 μm
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Discussion
The cellular function of C9orf72 has been under intensive
investigation since hexanucleotide repeat expansion in the
C9orf72 gene was shown to be the main cause of ALS/
FTLD [13, 38, 51], with reduced C9orf72 expression
proposed as one of the disease mechanisms [39]. In this
study, we searched for protein interactors for C9orf72 and
identified SMCR8 and WDR41 as two binding partners of
C9orf72, consistent with two recently published reports
[41, 53]. We further demonstrated that C9orf72/SMCR8/
Fig. 8 C9 deficiency in mice results in macrophage infiltration and increased levels of lysosomal proteins in the liver. a H&E staining of liver tissues
from 10 month old of WT or C9orf72 -/- mouse. (ii) and (iii) are high power magnification images of the hepatic parenchyma, arrowhead indicates
infiltrated immune cells; arrow points to necrotic hepatocyte. (v) and (vi) are high power magnification images of the hepatic portal area, arrowhead
indicates infiltrated immune cells. PV, portal vein. Scale bar: 500 μm in (i) and (iv), 100 μm in (ii, iii, v, vi) b Immunostaining of 4 month old liver sections
of WT and C9orf72-/- mice with anti-mouse CD68, prosaposin (PSAP), and progranulin (PGRN) antibodies. Nuclei are labelled with DAPI. Insert shows
representative CD68+ macrophage cells. Representative pictures from three pairs of mice are shown. Scale bar = 40 μm. c Immunostaining of 4 month
old liver sections of WT and C9orf72-/- mice with anti-mouse Lamp1, and cathepsin D (CathD) antibodies. Nuclei are labelled with DAPI. Insert shows
representative cells. Representative pictures from three pairs of mice are shown. Scale bar = 40 μm
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WDR41 interacts with the FIP200/Ulk1/ATG13/ATG101
complex involved in autophagy initiation. Our data also
showed that C9orf72 deficient mice display defects in au-
tophagy/lysosome pathway, supporting a critical role of
C9orf72 in autophagy/lysosome regulation.
Many other genes involved in membrane trafficking
and autophagy have been associated with ALS/FTLD, in-
cluding TBK1, OPTN, SQSTM1/p62, UBQLN2, VCP/
p97 and CHMP2B [19, 27, 36, 40]. Progranulin, the gene
mutated in a vast majority of FTLD with ubiquitin posi-
tive TDP-43 aggregates, was recently shown to play a
critical role in regulating lysosomal function [8, 42] and
the progranulin protein was shown to reside in the lyso-
some [17, 55]. TMEM106B, a risk factor for FTLD with
progranulin mutations, also regulates lysosomal morph-
ology and function [6, 9, 20, 25, 43]. Our current results
further support that dysfunction in the autophagy lyso-
some pathway is implicated in the disease progression of
ALS/FTLD caused by C9orf72 mutations. C9orf72 defi-
ciency in C. elegans and zebrafish has been shown to
result in locomotion defects [11, 46], supporting the no-
tion that C9orf72 haploinsufficiency could contribute to
ALS/FTLD progression. While neuron and glia specific
C9orf72 ablation or intracerebral mRNA knockdown does
not seem to cause motor neuron disease in mouse models
[22, 24], our data and recent data by others consistently
demonstrate that whole body C9orf72 deficiency produces
severe immune dysregulation in mice [2, 34]. In one study,
lysosomal abnormalities were also observed in microglia
isolated from C9orf72 deficient mice and in the motor
cortex and spinal cord of ALS patients with C9orf72 mu-
tations [34]. These findings strongly suggest that C9orf72
Fig. 9 Microglia do not show any obvious abnormalities in C9orf72 deficient mice. Brain sections from 10 month old WT and C9orf72-/- mice
were stained with anti-LAMP1, Iba1 and cathepsin D antibodies. Similar results were seen with 5 month old C9orf72-/- mouse. Scale bar = 50 μm
Fig. 10 C9 deficiency in mice leads to increased levels of autophagy-lysosome proteins in the spleen. a Western blot analysis of tissue lysates
from spleen, liver, and brain of WT and knockout mice. Representative pairs are shown. b Quantification of autophagy and lysosomal protein
levels in knockout mice relative to WT controls. Data are presented as Mean ± SEM, n = 3–6. *, p < 0.05; **, p < 0.01
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may regulate motor neuron survival through regulation of
inflammatory responses by affecting autophagy-lysosomal
function of microglia and macrophages. In contrast, our
studies failed to detect any obvious abnormalities of
microglia in our C9orf72 deficient mice (Fig. 9). It is pos-
sible that this may simply be due to our mice not being
old enough (10 months old) for us to detect a microglial
phenotype. It is also likely that microglial abnormalities
may become apparent in the C9orf72 deficient mice upon
additional insults to the nervous system.
The physical interaction between the C9orf72/SMCR8/
WDR41 complex and the autophagy initiation complex
FIP200/Ulk1/ATG13/ATG101 (Fig. 4) suggests that C9orf
72/SMCR8/WDR41 might regulate autophagy through the
FIP200/Ulk1/ATG13/ATG101 complex. However, exactly
how C9orf72/SMCR8/WDR41 regulates autophagy re-
mains unclear. It is interesting that WDR41 is enriched at
the Golgi, as the ER-Golgi intermediate compartment has
been shown to serve as a key membrane source for autop-
hagosome biogenesis [16]. One possibility is that C9orf72/
SMCR8/WDR41 serves as a substrate and a downstream
signaling component after Ulk1 activation. Interestingly,
SMCR8 was shown to be a substrate for Ulk1 in a recent
study [41]. This observation together with reduced autoph-
agy initiation in C9or72-/- spleen tissues argues that
C9orf72/SMCR8/WDR41 functions downstream of Ulk1
activation during autophagy activation. Autophagy defects
in C9orf72-/- mice might trigger upregulation of autophay/
lysosome genes to compensate for the defect. Although
we failed to identify any Rab GTPases as C9orf72 inter-
actors in our proteomic screen, C9orf72/SMCR8/WDR41
was shown to interact with Rab8a and Rab39b and func-
tions as a guanine nucleotide exchange factor (GEF) for
Rab GTPases in a recent study [41]. However, the effect
of Ulk1 phosphorylation on the GEF activities remains
to be determined. Future endeavors are needed to
further understand the mechanistic functions and regu-
lations of C9orf72/SMCR8/WDR41 complex at molecu-
lar and cellular levels. More studies are also needed to
characterize neuronal and microglial phenotypes due to
C9orf72 loss, possibly upon additional challenges, to
explain how C9orf72 deficiency contributes to ALS/
FTLD progression.
Conclusions
We describe the identification of two binding partners for
C9orf72: SMCR8 and WDR41. We demonstrated that
C9orf72/SMCR8/WDR41 interacts with the FIP200/Ulk1/
ATG13/ATG101 complex. We also generated C9orf72 defi-
cient mice and showed that loss of C9orf72 leads to macro-
phage infiltration in multiple organs. Additionally, C9orf72
deficiency leads to autophagy defects and increased levels
of many lysosomal proteins, supporting a critical role of
C9orf72 in regulating autophagy/lysosomal pathway and
inflammation in vivo.
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